[Featured Stock] EOPLLOW Highlights Investment Appeal Compared to 19 Trillion Insulet... The World's Only Disposable Insulin Pump Competitor

[Asia Economy Reporter Hyungsoo Park] EOPFlow is soaring. It appears that the stock price was influenced by the assessment that the company laid the groundwork to surpass Insulet after raising funds earlier this year.

At 9:46 AM on the 9th, EOPFlow was trading at 61,700 KRW, up 16.42% from the previous day.

Donggeon Lee, a researcher at Shinhan Financial Investment, explained, "EOPFlow raised 35 billion KRW in funds to accelerate corporate acquisitions and research and development for new business ventures," adding, "The funds will be used for the development of new wearable drug infusion devices and related investments, clinical trials and R&D of wearable artificial pancreas, and R&D and license acquisition of a subsidiary related to wearable artificial kidneys in the U.S."

He continued, "With the fundraising, the company succeeded in laying the foundation to surpass Insulet," and added, "Insulet's sales of drug infusion devices other than insulin account for about 10% of its total sales, confirming its importance in terms of both proportion and growth."

Furthermore, he said, "EOPFlow expects meaningful sales in the drug infusion device market not only with EOPatch, the artificial pancreas product line EOPatch X, and EOPani, but also in the artificial kidney business, which is a new market that Insulet has not entered. As sales begin to ramp up, EOPFlow's competitiveness will be further strengthened."

The researcher explained, "EOPFlow is smoothly progressing from the domestic launch of EOPatch on March 29, to the acquisition of CE certification in May and the start of sales to European partners, as well as contracts and entry into the U.S. distribution partner market." He emphasized, "Considering expansion into the artificial pancreas and artificial kidney markets and entry into the drug infusion device market beyond insulin, EOPFlow remains highly attractive compared to Insulet."

He analyzed, "Especially since Insulet's market capitalization remains high at 18.9 trillion KRW despite recent market adjustments, this is positive for EOPFlow's stock price as the global sole competitor in disposable insulin pumps."